Resistant gram-negative bacilli: A neglected healthcare crisis?

American Journal of Health-System Pharmacy

Volumn 64, Issue 23 SUPPL. 14, 2007, Pages

  Lautenbach, Ebbing ^a   Polk, Ron E ^b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Antiinfective agents; Control; Dosage; Epidemiology; Gram negative bacteria; Gram negative bacterial infections; Protocols; Resistance

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFTAZIDIME; CEPHALOSPORIN; DORIPENEM; ERYTHROMYCIN; GENTAMICIN; IMIPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SULTAMICILLIN;

ANTIBIOTIC RESISTANCE; AREA UNDER THE CURVE; BACTERIAL INFECTION; BACTERIAL TRANSMISSION; BACTERIAL VIRULENCE; CLINICAL PRACTICE; CONFERENCE PAPER; DOSE RESPONSE; DRUG COST; DRUG EFFICACY; DRUG FORMULATION; DRUG POTENCY; DRUG PROGRAM; ENTEROBACTER INFECTION; GRAM NEGATIVE BACTERIUM; GRAM NEGATIVE INFECTION; HEALTH CARE POLICY; HEALTH SERVICE; HUMAN; INCIDENCE; INTERVENTION STUDY; PRESCRIPTION; PRIORITY JOURNAL; PROPHYLAXIS; PROSPECTIVE STUDY; RISK FACTOR; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 36749067251     PISSN: 10792082     EISSN: None     Source Type: Journal    
DOI: 10.2146/ajhp070477     Document Type: Conference Paper

References (71)

1. Patterson JE. Multidrug-resistant gram-negative pathogens: multiple approaches and measures for prevention. Infect Control Hosp Epidemiol. 2006; 27:889-92.
2. Harris AD, McGregor JC, Furuno JP. What infection control interventions should be undertaken to control multidrug-resistant gram-negative bacteria. Clin Infect Dis. 2006; 43(Suppl 2):S57-S61.
3. Spellberg B, Powers JH, Brass EP et al. Trends in antimicrobial drug development: implications for the future. Clin Infect Dis. 2004; 38:1279-86.
4. Pittet D, Wenzel RP. Nosocomial bloodstream infections. Secular trends in rates, mortality, and contribution to total hospital deaths. Arch Intern Med. 1995; 155:1177-84.
5. Banerjee SN, Emori TG, Culver DH et al. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National Nosocomial Infections Surveillance System. Am J Med. 1991; 91(Suppl 3B):86S-89S.
6. Albrecht SJ, Fishman NO, Kitchen J et al. Reemergence of gram-negative health care-associated bloodstream infections. Arch Intern Med. 2006; 166:1289-94.
7. Talbot GH, Bradley J, Edwards JE Jr et al. Bad bugs need drugs: an update on the development pipeline from the Antimicrobial Availability Task Force of the Infectious Diseases Society of America. Clin Infect Dis. 2006; 42:657-68.
8. National Nosocomial Infections Surveillance System. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issue October 2004. Am J Infect Control. 2004; 32:470-85.
9. Flamm RK, Weaver MK, Thornsberry C et al. Factors associated with relative rates of antibiotic resistance in Pseudomonas aeruginosa isolates tested in clinical laboratories in the United States from 1999 to 2002. Antimicrob Agents Chemother. 2004; 48:2431-36.
10. Iversen BG, Eriksen HM, Bo G et al. Pseudomonas aeruginosa contamination of mouth swabs during production causing a major outbreak. Ann Clin Microbiol Antimicrob. 2007a; 6:3.
11. Iversen BG, Jacobsen T, Eriksen HM et al. An outbreak of Pseudomonas aeruginosa infection caused by contaminated mouth swabs. Clin Infect Dis. 2007b; 44:794-801.
12. Srinivasan A, Wolfenden LL, Song X et al. An outbreak of Pseudomonas aeruginosa infections associated with flexible bronchoscopes. N Engl J Med. 2003; 348:221-7.
13. Berlau J, Aucken H, Malnick H et al. Distribution of Acinetobacter species on skin of healthy humans. Eur J Clin Microbiol Infect Dis. 1999;18:179-83.
14. Gaynes R, Edwards JR, the National Nosocomial Infections Surveillance System. Overview of nosocomial infections caused by gram-negative bacilli. Clin Infect Dis. 2005; 41:848-54.
15. Falagas ME, Siempos II, Bliziotis IA et al. Administration of antibiotics via the respiratory tract for the prevention of ICU-acquired pneumonia: a meta-analysis of comparative trials. Crit Care 2006; 10(4):R123.
16. Fournier PE, Richet H. The epidemiology and control of Acinetobacter baumannii in health care facilities. Clin Infect Dis. 2006; 42:692-9.
17. Itokazu GS, Quinn JP, Bell-Dixon C et al. Antimicrobial resistance rates among aerobic gram-negative bacilli recovered from patients in intensive care units: evaluation of a national postmarketing surveillance program. Clin Infect Dis. 1996; 23:779-84.
18. Burwen DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. National Nosocomial Infections Surveillance System. J Infect Dis. 1994; 170:1622-5.
19. Lautenbach E, Patel JB, Bilker WB et al. Extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for infection and impact of resistance on outcomes. Clin Infect Dis. 2001;32:1162-71.
20. Jacoby GA. Extended-spectrum β-lactamases and other enzymes providing resistance to oxyimino-β-lactams. Infect Dis Clin North Am. 1997; 11:875-87.
21. Gupta A, Della-Latta P, Todd B et al. Outbreak of extended-spectrum- β-lactamase-producing Klebsiella pneumoniae in a neonatal intensive care unit linked to artificial nails. Infect Control Hosp Epidemiol. 2004; 25:210-5.
22. Gastmeier P, Groneberg K, Weist K et al. A cluster of nosocomial Klebsiella pneumoniae bloodstream infections in a neonatal intensive care department: identification of transmission and intervention. Am J Infect Control. 2003; 31:424-30.
23. Boszczowski I, Nicoletti C, Puccini DM et al. Outbreak of extended spectrum β-lactamase producing Klebsiella pneumoniae in a neonatal intensive care unit related to onychomycosis in a health care worker. Pediatr Infect Dis J. 2005; 24:648-50.
24. Rahal JJ, Urban C, Horn D et al. Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella. JAMA. 1998; 280:1233-7.
25. Cassettari VC, Silveira IR, Balsamo AC et al. Outbreak of extended-spectrum β-lactamase-producing Klebsiella pneumoniae in an intermediate-risk neonatal unit linked to onychomycosis in a healthcare worker. J Pediatr (Rio J). 2006; 82:313-6.
26. Cohen ML. Epidemiology of drug resistance: implications for a post-antimicrobial era. Science. 1992; 257: 1050-5.
27. Holmberg SD, Solomon SL, Blake PA. Health and economic impacts of antimicrobial resistance. Rev Infect Dis. 1987; 9:1065-78.
28. Cosgrove SE. The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital stay, and health care costs. Clin Infect Dis. 2006; 42(Suppl 2):S82-S89.
29. U.S. Congress, Office of Technology Assessment. Impacts of antibiotic-resistant bacteria, OTA-H-629. Washington, D.C.: U.S. Government Printing Office, 1995.
30. Vergis EN, Hayden MK, Chow JW et al. Determinants of vancomycin resistance and mortality rates in enterococcal bacteremia. A prospective multicenter study. Ann Intern Med. 2001; 135:484-92.
31. Blot SI, Vandewoude KH, Hoste EA et al. Outcome and attributable mortality in critically ill patients with bacteremia involving methicillin-susceptible and methicillin-resistant Staphylococcus aureus. Arch Intern Med. 2002; 162:2229-35.
32. Cosgrove SE, Carmeli Y. The impact of antimicrobial resistance on health and economic outcomes. Clin Infect Dis. 2003; 36:1433-7.
33. Vila J, Simon K, Ruiz J et al. Are quinolone-resistant uropathogenic Escherichia coli less virulent? J Infect Dis. 2002; 186:1039-42.
34. Blazquez R, Menasalvas A, Carpena I et al. Invasive disease caused by ciprofloxacin-resistant uropathogenic Escherichia coli. Eur J Clin Microbiol Infect Dis. 1999; 18:503-5.
35. Maslow JN, Lautenbach E, Bilker WB et al. Colonization with extraintestinal pathogenic Escherichia coli among nursing home residents and its relationship to fluoroquinolone resistance. Antimicrob Agents Chemother. 2004; 48:3618-20.
36. Ibrahim EH, Sherman G, Ward S et al. The influence of inadequate antimicrobial treatment of bloodstream infections on patient outcomes in the ICU setting. Chest. 2000; 118:146-55.
37. Hyle EP, Lipworth AD, Zaoutis TE et al. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum β-lactamase- producing Enterobacteriaceae: variability by site of infection. Arch Intern Med. 2005; 165:1375-80.
38. Fishman N. Antimicrobial Stewardship. Am J Med. 2006; 119:S53-S61.
39. Paterson DL. The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals. Clin Infect Dis. 2006;42:S90-S95.
40. MacDougall C, Polk RE. Antimicrobial stewardship programs in health care systems. Clin Micro Rev. 2005; 18:638-56.
41. Owens RC, Fraser GL, Stogsdill P. Antimicrobial stewardship programs as a means to optimize antimicrobial use. Pharmacotherapy. 2004; 24:896-908.
42. Dellit TH, Owens RC, McGowan JE Jr et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007; 44:159-77.
43. Carling P, Fung T, Killion A et al. Favorable impact of a multidisciplinary antibiotic management program conducted during 7 years. Infect Control Hosp Epidemiol. 2003; 24:699-706.
44. Fridkin SK, Steward CD, Edwards JR et al. Surveillance of antimicrobial use and antimicrobial resistance in United States hospitals: Project I CARE phase 2. Clin Infect Dis. 1999; 29:245-252.
45. Burke J. Antibiotic resistance - squeezing the balloon? JAMA. 1998; 280:1270-1.
46. Landman D, Chockalingam M, Quale JM. Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary. Clin Infect Dis. 1999; 28:1062-6.
47. Martin CE, Ofotokun I, Rapp R et al. Results of an antimicrobial control program at a university hospital. Am J Health-Syst Pharm. 2005; 62:732-8.
48. Polk RE, Letcavage J, Mahoney A et al. Adult antibiotic usage in 131 US hospitals: comparison of Defined Daily Dose (DDD) to Duration of Therapy (DOT)/1000 patient days (PD). Clin Infect Dis. 2007; 44:664-70.
49. Schwaber MJ, De-Medina T, Carmeli Y. Epidemiological interpretation of antibiotic resistance studies - what are we missing? Nature Rev. 2004; 2: 979-83.
50. Davey P, Brown E, Fenelon L et al. Systematic review of antimicrobial drug prescribing in hospitals. Emerg Infect Dis. 2006; 12:211-6.
51. Stone SP, Cooper BS, Kibbler CC et al. The ORION statement: guidelines for transparent reporting of outbreak reports and intervention studies of nosocomial infection. J Antimicrob Chemother. 2007; 59:833-40.
52. Lipworth AD, Hyle EP, Fishman NO et al. Limiting the emergence of extended-spectrum β-lactamase-producing Enterobacteriaceae: influence of patient population characteristics on the response to antimicrobial formulary interventions. Infect Control Hosp Epidemiol. 2006; 27:279-86.
53. Sunenshine RH, Liedtke LA, Jemigan DB et al. Role of infectious diseases consultants in management of antimicrobial use in hospitals. Clin Infect Dis. 2004; 38:934-8.
54. Bergstrom CT, Lo M, Lipsitch M. Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals. Proc Nat Acad Science USA. 2004; 101:13285-90.
55. Drusano GL. Pharmacokinetics and pharmacodynamics of antimicrobials. Clin Infect Dis. 2007; 45(Suppl 1):S89-95.
56. Ambrose PG, Bhavnani SM, Rubino CM et al. Pharmacokinetics - pharmacodynamics of antimicrobial therapy: It's not just for mice anymore. Clin Infect Dis. 2007; 44:79-86.
57. Zhanel GG. Influence of pharmacokinetic and pharmacodynamic principles on antibiotic selection. Curr Infect Dis Reports. 2001; 3:29-34.
58. Bhavnani S, Hammel JP, Cirincione BB et al. Use of pharmacokinetic- pharmacodynamic target attainment analyses to support phase 2 and 3 dosing strategies for doripenem. Antimicrob Agents Chemother. 2005; 49:3944-7.
59. Rybak MJ. Pharmacodynamics: relation to antimicrobial resistance. Am J Med. 2006; 119:S37-S44.
60. Jumbe N, Louie A, Leary R et al. Application of a mathematical model to prevent in vivo amplification of antibiotic-resistant bacterial populations during therapy. J Clin Invest. 2003;112:275-85.
61. Hoban DJ. Antibiotics and collateral damage. Clin Cornerstone. 2003; Suppl 3:S12-S20.
62. Muto CA, Jernigan JA, Ostrowsky BE et al. SHEA guideline for preventing nosocomial transmission of multidrug-resistant strains of Staphylococcus aureus and Enterococcus. Infect Control Hosp Epidemiol. 2003; 24:362-86.
63. Paterson DL. The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis. 2006; 43(Suppl 2):43-8.
64. Garner JS. Guideline for isolation precautions in hospitals. The Hospital Infection Control Practices Advisory Committee [erratum appears in Infect Control Hosp Epidemiol. 1996; 17:214]. Infect Control Hosp Epidemiol. 1996; 17:53-80.
65. CDC. Guideline for the prevention of nosocomial pneumonia. MMWR. 1997; 46(No. RR-1).
66. CDC. Guidelines for preventing healthcare-associated pneumonia, 2003. Atlanta, GA: US Department of Health and Human Services, CDC 2004. www.cdc.gov/ncidod/hip/pneumonia/default.htm (accessed 2007 September 5).
67. CDC. Guidelines for preventing healthcare-associated pneumonia, 2003. Recommendations of the CDC and the Healthcare Infection Control Practices Advisory Committee. Respir Care. 2004; 49:926-39.
68. Pittet D, Hugonnet S, Harbarth S et al. Effectiveness of a hospital-wide programme to improve compliance with hand hygiene. Infection Control Programme. Lancet. 2000; 356:1307-12.
69. Bhalla A, Pultz NJ, Gries DM et al. Acquisition of nosocomial pathogens on hands after contact with environmental surfaces near hospitalized patients. Infect Control Hosp Epidemiol. 2004; 25:164-7.
70. Srinivasan A, Song X, Ross T et al. A prospective study to determine whether cover gowns in addition to gloves decrease nosocomial transmission of vancomycin-resistant enterococci in an intensive care unit. Infect Control Hosp Epidemiol. 2002; 23:424-8.
71. Puzniak LA, Leet T, Mayfield J et al. To gown or not to gown: the effect on acquisition of vancomycin-resistant enterococci. Clin Infect Dis. 2002; 35:18-25.